Sponsor a session on the program at AusBiotech 2018

 

Align your brand with a relevant session

$7,600 for members | $9,900 for nonmembers

Inclusions:

Opportunity to provide a chair in one of the below sessions which includes a conference day pass 
One (1) full conference registration
Opportunity to provide printed material to delegates during the session
Logo included on the holding slide during the nominated session and in the program and on the event website
Opportunity to provide a gobo for logo projection during the during the nominated session
Acknowledgement in electronic and printed materials leading up to and during AusBiotech 2018
Acknowledgement within pre and post marketing activities 

* approval is required from the program committee regarding suitability

 

Topics

Global life science investing and industry update
John Carroll, Editor in Chief, Endpoints 

 

Keeping the balance in your clinical portfolio - prioritisation versus doing it all
Dr Charmaine Gittleson, Chief Medical Officer, CSL Limited

 

Precision medicines: maintaining competitiveness in the post-human genome project era
This session will discuss the progression of precision medicines onto to the Australian market, implications for the industry and strategies to help Australian companies maintain global competitiveness in the post-human genome project era

 

The anatomy of a deal
This session provides valuable insights from a spectrum of stakeholders with experience in developing complex deals with multinationals in licensing, providing a service or a product

 

Big pharma panel:

Liz Chatwin, Country President, AstraZeneca Aust/NZ

Ben Thorner, Senior Vice President & Head of Business Development & Licensing, Merck Research Laboratories

Kathy Connell, Senior Director, New Ventures ANZ, Johnson & Johnson Innovation

Dr Anand Gautam, Senior Director & Head, External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer

Dr Stephen Hitchcock, Head of Research, Takeda Pharmaceutical 

 

New gene technology in diagnostics, vaccines and CAR-T therapies

 

Gender diversity in Australian biotech
#metoo - A closer look at women in leadership positions, exploring how Australia measures up in terms of women in senior roles, questioning the progress and issues facing women in life sciences

 

Commercialising medicinal cannabis in Australia's evolving regulatory environment
Medical cannabis is legalised in many countries & approved in Australia in late 2016.  A number of medical conditions can be treated with cannabis extracts including chronic pain & chemotherapy nausea. There is patient confusion & frustration as the first companies navigate the complex regulatory environment & gain medical acceptance through doctor education. This session will outline the opportunity & progress in getting quality medical cannabis to Australian patient

 

From bench to bedside: GPCR drug discovery

Despite significant market size, over 80% of GPCR targets are yet to be effectively exploited. This session will explore GPCRs in a number of therapeutic areas

 

Clinical Trials Stream - Niche (neurological) clinical trial capabilities in Australia
How we work with biotechnology companies to deliver their project

 

Investor session panel: 

John Carroll, Editor in Chief, Endpoint

James Ieong, Head of IC – Chairman, Pagoda Investment

Karimah Es Sabar, Chief Executive Officer & Partner, Quark Venture (invited)

Dr Elaine Stead (invited)

 

Update on the Innovation, Science and Research System Review/Strategic Plan
Dr Charlie Day, Chief Executive Officer, Office of Innovation & Science Australia

 

Artificial intelligence
The future of medical imaging and the basis and future of data mining and artificial intelligence 

 

Creating investor value - recent Australian public company exits